Skip to main content

High-Efficacy Therapy Cuts Disability Progression in Pediatric MS

Medically reviewed by Carmen Pope, BPharm. Last updated on April 14, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, April 12, 2024 -- Treatment of pediatric-onset relapsing-remitting multiple sclerosis with high-efficacy therapy reduces the risk for transition across disability states, according to a study published in the May issue of The Lancet Child and Adolescent Health.

Sifat Sharmin, Ph.D., from the University of Melbourne in Australia, and colleagues examined how high-efficacy therapies influence transition across five disability states in individuals with pediatric-onset multiple sclerosis. Data were included from 151 centers across 41 countries. People with onset of multiple sclerosis symptoms at younger than 18 years were included if they had a confirmed diagnosis of relapsing-remitting multiple sclerosis and at least four Expanded Disability Status Scale scores recorded. Overall, 5,224 patients were included.

The researchers observed a reduction in the risk for disability worsening across the disability states with high-efficacy therapies. Compared with those who remained untreated, those treated with high-efficacy therapies while in the minimal disability state had the largest reduction (hazard ratio, 0.41). There was a decline seen in the benefit of high-efficacy therapies with increasing disability. Compared with those who remained untreated, young people with minimal disability who received low-efficacy therapy also experienced a reduced risk for transitioning to mild disability (hazard ratio, 0.65).

"The new perspective presented here on the effect of early high-efficacy therapies for preserving neurological function among people with pediatric-onset multiple sclerosis provides a useful addition to the information guiding policy governing access to disease-modifying therapies in children with multiple sclerosis," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Generic Medications Can Keep OOP Costs Down for Neurological Conditions

WEDNESDAY, Oct. 30, 2024 -- Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, for which costs continue to...

Cognitive Therapy, Modafinil, Combo All Beneficial for Multiple Sclerosis Fatigue

FRIDAY, Oct. 25, 2024 -- Cognitive behavioral therapy (CBT), modafinil, and their combination are equally beneficial for multiple sclerosis fatigue, according to a study published...

Cancer Incidence Increased for People With Multiple Sclerosis

WEDNESDAY, Oct. 9, 2024 -- Cancer incidence is increased overall in people with multiple sclerosis (PwMS), with considerable differences depending on cancer type, age, and sex...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.